Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
98.31
-0.70 (-0.71%)
At close: Feb 27, 2026, 4:00 PM EST
96.44
-1.87 (-1.90%)
After-hours: Feb 27, 2026, 7:22 PM EST
Revvity Revenue
In the year 2025, Revvity had annual revenue of $2.86B with 3.67% growth. Revvity had revenue of $772.06M in the quarter ending December 28, 2025, with 5.85% growth.
Revenue (ttm)
$2.86B
Revenue Growth
+3.67%
P/S Ratio
3.85
Revenue / Employee
$259,641
Employees
11,000
Market Cap
10.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2025 | 2.86B | 101.03M | 3.67% |
| Dec 29, 2024 | 2.76B | 4.46M | 0.16% |
| Dec 31, 2023 | 2.75B | -561.25M | -16.95% |
| Jan 1, 2023 | 3.31B | -515.99M | -13.48% |
| Jan 2, 2022 | 3.83B | 1.16B | 43.73% |
| Jan 3, 2021 | Pro | Pro | Pro |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.04B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.34B |
| Charles River Laboratories International | 4.02B |
| Exact Sciences | 3.25B |
| Medpace Holdings | 2.53B |
| Qiagen | 2.09B |
RVTY News
- 11 days ago - Revvity to Present at Upcoming Investor Conferences - Business Wire
- 23 days ago - Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026 - Business Wire
- 25 days ago - Revvity: Close To A Buy, Not Quite There - Seeking Alpha
- 25 days ago - Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results - Benzinga
- 26 days ago - Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers - Benzinga
- 26 days ago - Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter - Reuters
- 26 days ago - Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025 - Business Wire